Appearing as a significant breakthrough in the battle against obesity, the drug is capturing considerable attention . This treatment combines effects of two established GLP-1 binding agonists, dulaglutide , plus an unique glucose-dependent incretin component. Initial patient results have shown significant body loss in patients with excessive we… Read More